Status:

TERMINATED

Toxicity Substudy of Evaluation of Subcutaneous Proleukin in a Randomised International Trial (ESPRIT): TOXIL-2 Substudy

Lead Sponsor:

Kirby Institute

Collaborating Sponsors:

The University of New South Wales

Conditions:

HIV Infections

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This substudy is an open-label, randomised study comparing the uptake of recombinant interleukin-2 (rIL-2) in HIV-1 infected individuals receiving different combinations of antiemetics and analgesic a...

Detailed Description

The research is a randomised open-label substudy of ESPRIT. The substudy is exploring whether the amount of rIL-2 taken during a dosing cycle of rIL-2 can be increased through controlling the predicta...

Eligibility Criteria

Inclusion

  • Patients participating in ESPRIT and randomised to the rIL-2 arm, who:
  • Are not at CD4+ T-cell target for the protocol
  • Have not received rIL-2 for \> 2 months
  • Have reported both GI upset and constitutional side-effects as one of the reasons for either dose modifying in prior cycles or unwillingness to receive further rIL-2
  • Are considered by the Investigator as medically safe to receive further dosing with rIL-2
  • Are willing to receive further dosing with rIL-2 at the dose specified by the Investigator
  • Are willing to sign informed consent to participate in the substudy

Exclusion

  • All exclusions for the receipt of rIL-2 on ESPRIT
  • Known allergy to non-steroidal anti-inflammatory drugs (NSAIDs), opiates, 5HT-3 (serotonin-3) inhibitors, anti-dopaminergic antiemetics, or any other components of the proposed adjunct regimens.
  • Use of other NSAIDs (cyclooxygenase-2 \[COX-2\] inhibitors, corticosteroids) or opiate analgesics within two weeks of rIL-2 dosing. Use of low dose aspirin as a cardio-protective agent is allowed.

Key Trial Info

Start Date :

November 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2008

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT00147355

Start Date

November 1 2005

End Date

December 1 2008

Last Update

April 12 2012

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

Hospital General de Agudos JM Ramos Mejia

Buenos Aires, Buenos Aires, Argentina, C221

2

FUNCEI

Buenos Aires, Buenos Aires, Argentina

3

Hospital Italiano de Buenos Aires

Buenos Aires, Buenos Aires, Argentina

4

Hospital Prof. Alejandro Posadas

Buenos Aires, Argentina